Business
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled f
About this update from Journey Medical Corporation
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hjjUQ.iXZdhdLwOzj17HjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"Initial distribution of Emrosi to pharmacies ongoing","length":52,"tagName":"p"},{"type":"text","content":"First prescriptions of Emrosi filled","length":36,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults. Emrosi is available by prescription at specialty pharmacy chains.","length":662,"tagName":"p"},{"type":"text","content":"Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, “We are thrilled that the initial distribution to pharmacies is ongoing and the first Emrosi prescriptions have been filled. Rosacea is a challenging condition that affects millions, and Emrosi, the lowest-dose oral minocycline on the market, delivers significantly superior clinical outcomes for rosacea compared to Oracea® and placebo, while maintaining a comparable safety profile, as demonstrated in clinical trials. The launch of Emrosi marks a major milestone for Journey Medical and underscores our commitment to improving the quality of life for those living with dermatology conditions such as rosacea.”","length":704,"tagName":"p"},{"type":"text","content":"The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November 2024.","length":104,"tagName":"p"},{"type":"text","...